Get startedLog in
    Picture of Xilio Therapeutics logo

    XLO — Xilio Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapTurnaround
    All News

    Brief: Xilio Therapeutics Announces Pipeline And Business Updates For Q4 And Full Year 2022 Financial Results

    Picture of Xilio Therapeutics logoXilio Therapeutics
    02/03/2023 21:19
    March 2 (Reuters) - Xilio Therapeutics Inc  XLO.O :
    * XILIO THERAPEUTICS ANNOUNCES PIPELINE AND BUSINESS UPDATES
FOR
THE FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
    * INITIAL CLINICAL DATA FROM XTX101, XTX202 AND XTX301
CLINICAL
TRIALS ANTICIPATED IN 2023
    * ANTICIPATE INITIATING PHASE 2 MONOTHERAPY CLINICAL TRIAL
FOR
XTX202 IN MELANOMA AND RENAL CELL CARCINOMA IN APRIL 2023
    * ENDED 2022 WITH $120.4 MILLION IN CASH AND CASH
EQUIVALENTS;
CONTINUE TO ANTICIPATE CASH RUNWAY INTO Q2 OF 2024
    * QTRLY  LOSS PER SHARE $0.82
    * Q4 EARNINGS PER SHARE VIEW $-0.79 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX6tXn3K 
Further company coverage:  XLO.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Xilio Therapeutics

    See all news